The Quest Trial, a paradigm of HIV collaborative research

被引：5

作者：

Goh, LE ^{[1
]}

McDade, H

Kinloch, S

Perrin, L

Cooper, D

Phillips, A

Hoen, B

Autran, B

Sonnerborg, A

Tsoukas, C

机构：

[1] GlaxoWellcome HIV Clin Res, London, England

[2] UCL Royal Free Hosp, London NW3 2QG, England

[3] Univ Geneva, Geneva, Switzerland

[4] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia

[5] UCL Royal Free & Univ Coll, Sch Med, London, England

[6] Univ Besancon, Med Ctr, F-25030 Besancon, France

[7] Hop La Pitie Salpetriere, Lab Immunol Cellulaire & Tissulaire, Paris, France

[8] Karolinska Inst, Stockholm, Sweden

[9] Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada

来源：

NATURE MEDICINE | 2000年 / 6卷 / 11期

关键词：

D O I：

10.1038/81251

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：1194 / 1194

页数：1

共 3 条

[1] Industry outlines its perspective on new Third-World vaccine development [J].

Birmingham, K .

NATURE MEDICINE, 2000, 6 (07) :723-724

[2] Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].

Finzi, D ;

Blankson, J ;

Siliciano, JD ;

Margolick, JB ;

Chadwick, K ;

Pierson, T ;

Smith, K ;

Lisziewicz, J ;

Lori, F ;

Flexner, C ;

Quinn, TC ;

Chaisson, RE ;

Rosenberg, E ;

Walker, B ;

Gange, S ;

Gallant, J ;

Siliciano, RF .

NATURE MEDICINE, 1999, 5 (05) :512-517

[3]

Walker BD, 1998, SCIENCE, V279, P1436

← 1 →